These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29146129)

  • 1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study.
    Descalzo MA; Carretero G; Ferrándiz C; Rivera R; Daudén E; Gómez-García FJ; de la Cueva P; Herrera-Ceballos E; Belinchón I; López-Estebaranz JL; Alsina M; Sánchez-Carazo JL; Ferrán M; Baniandrés O; Carrascosa JM; Llamas-Velasco M; Ruiz-Genao D; Herrera-Acosta E; Muñoz-Santos C; García-Doval I;
    J Am Acad Dermatol; 2018 Apr; 78(4):798-800. PubMed ID: 29146129
    [No Abstract]   [Full Text] [Related]  

  • 2. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts.
    García-Doval I; Hernández MV; Vanaclocha F; Sellas A; de la Cueva P; Montero D;
    Br J Dermatol; 2017 Mar; 176(3):643-649. PubMed ID: 27258623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious infections among a large cohort of subjects with systemically treated psoriasis.
    Dobry AS; Quesenberry CP; Ray GT; Geier JL; Asgari MM
    J Am Acad Dermatol; 2017 Nov; 77(5):838-844. PubMed ID: 28917384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug survival rates and reasons for drug discontinuation in psoriasis.
    Arnold T; Schaarschmidt ML; Herr R; Fischer JE; Goerdt S; Peitsch WK
    J Dtsch Dermatol Ges; 2016 Nov; 14(11):1089-1099. PubMed ID: 27879076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
    Weisenseel P; Reich K; Griemberg W; Merten K; Gröschel C; Gomez NN; Taipale K; Bräu B; Zschocke I
    J Dtsch Dermatol Ges; 2017 Feb; 15(2):180-186. PubMed ID: 28214304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS).
    Thaçi D; Weisenseel P; Philipp S; Rosenbach T; Rotterdam S; Augustin M; Neureither M; Reich K
    J Dtsch Dermatol Ges; 2013 May; 11(5):429-35. PubMed ID: 23433431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
    Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
    J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
    Hoffmann JH; Knoop C; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2017 Jun; 97(6):705-710. PubMed ID: 28224166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
    Garcia-Doval I; Carretero G; Vanaclocha F; Ferrandiz C; Daudén E; Sánchez-Carazo JL; Alsina M; Herrera-Ceballos E; Gómez-García FJ; Ferrán M; López-Estebaranz JL; Hernanz JM; Belinchón-Romero I; Vilar-Alejo J; Rivera R; Carrascosa JM; Carazo C
    Arch Dermatol; 2012 Apr; 148(4):463-70. PubMed ID: 22508869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study.
    Chen YJ; Chang YT; Shen JL; Chen TT; Wang CB; Chen CM; Wu CY
    Arthritis Rheum; 2012 Jun; 64(6):1879-87. PubMed ID: 22161801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse events, healthcare interventions and healthcare utilization during home infusion therapy with daptomycin and vancomycin: a propensity score-matched cohort study.
    Shrestha NK; Mason P; Gordon SM; Neuner E; Nutter B; O'Rourke C; Rehm SJ
    J Antimicrob Chemother; 2014 May; 69(5):1407-15. PubMed ID: 24398341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).
    Papp KA; Langley RG; Lebwohl M; Krueger GG; Szapary P; Yeilding N; Guzzo C; Hsu MC; Wang Y; Li S; Dooley LT; Reich K;
    Lancet; 2008 May; 371(9625):1675-84. PubMed ID: 18486740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
    van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
    Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
    Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
    Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
    JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report].
    Rivera R; García-Doval I; Carretero G; Daudén E; Sánchez-Carazo J; Ferrándiz C; Herrera E; Alsina M; Ferrán M; López-Estebaranz JL; Gómez F; Herranz JM; Carrascosa JM; Vanaclocha F;
    Actas Dermosifiliogr; 2011 Mar; 102(2):132-41. PubMed ID: 21377137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The search for effective and safe disease control in psoriasis.
    Naldi L
    Lancet; 2008 Apr; 371(9621):1311-2. PubMed ID: 18424307
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.